Promega Corporation Enters License Agreement with Broad Institute to Access CRISPR-Cas9 Gene Editing Technology
Promega Corporation announced today it has signed a non-exclusive license agreement with the Broad Institute of MIT and Harvard to sell tools and reagents for CRISPR-Cas9 gene editing, providing scientists new tools for interrogating endogenous biology. Under the agreement, Promega will combine CRISPR-Cas9 technology with its products that knock-in Promega genetic reporters to the genomes of... Read more